https://www.proactiveinvestors.co.uk Proactiveinvestors RSS feed en Thu, 18 Oct 2018 20:42:28 +0100 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[News - OptiBiotix boss Stephen O’Hara highlights recent direct share purchases in Proactive interview ]]> https://www.proactiveinvestors.co.uk/companies/news/207210/optibiotix-boss-stephen-ohara-highlights-recent-direct-share-purchases-in-proactive-interview-207210.html Stephen O’Hara, the boss of OptiBiotix Health plc (LON:OPTI), has highlighted recent share purchases by two of its non-executive directors over the past few months.

Chairman Neil Davidson, who also sits on the board of WM Morrison Supermarkets PLC (LON:MRW), and Sean Christie have snapped up almost £400,000 worth of shares since July.

Christie was previously group finance director at chemicals group Croda and food group Northern Foods, while Davidson was chief executive at Express Dairies and Arla Foods.

In an interview with Proactive Investors, O’Hara said: “It’s really reassuring to ourselves within OptiBiotix and hopefully to investors that two big industry players…have committed large amounts of money to the company.

“That this is from industry leaders like [Sean and Neil] is very reassuring for the company in what we’re doing. I think what they see is the potential for the company going forward.”

He added: “We’re growing rapidly and we’re on that turn now between a company that has been developing products to commercialising products.

“We’re getting to a point where our costs are being covered month-to-month and as we go forward, if we sustain that, we’ll grow to profitability in 2019, so it’s an exciting time for a growing company.”

OptiBiotix shares were down 4.4% on Tuesday afternoon to 76.0p.

]]>
Tue, 16 Oct 2018 15:52:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/207210/optibiotix-boss-stephen-ohara-highlights-recent-direct-share-purchases-in-proactive-interview-207210.html
<![CDATA[Media files - OptiBiotix CEO Stephen O'Hara on recent deals and director share purchase ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/10847/optibiotix-ceo-stephen-o-hara-on-recent-deals-and-director-share-purchase-10847.html Mon, 15 Oct 2018 10:30:00 +0100 https://www.proactiveinvestors.co.uk/companies/stocktube/10847/optibiotix-ceo-stephen-o-hara-on-recent-deals-and-director-share-purchase-10847.html <![CDATA[RNS press release - Director's Dealing ]]> https://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20181011070008_13824302/ Thu, 11 Oct 2018 07:00:08 +0100 https://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20181011070008_13824302/ <![CDATA[Media files - OptiBiotix Health signs manufacturing and supply agreement with US Pharma Lab ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/10788/optibiotix-health-signs-manufacturing-and-supply-agreement-with-us-pharma-lab-10788.html Tue, 09 Oct 2018 14:41:00 +0100 https://www.proactiveinvestors.co.uk/companies/stocktube/10788/optibiotix-health-signs-manufacturing-and-supply-agreement-with-us-pharma-lab-10788.html <![CDATA[News - OptiBiotix inks agreement to manufacture LPLDL in US market ]]> https://www.proactiveinvestors.co.uk/companies/news/206637/optibiotix-inks-agreement-to-manufacture-lpldl-in-us-market-206637.html OptiBiotix Health plc (LON:OPTI) has signed a manufacturing and supply agreement with a US-based probiotic maker for its LPLDL probiotic strain.

The biotech firm said under the agreement, US Pharma Lab Inc (USPL) would be granted non-exclusive rights to manufacture and supply formulations containing the LPLDL strain.

READ: OptiBiotix Health unveils second distribution deal of the week for weight management product

USPL is a family owned business with facilities in the US, India, and China which focuses on the handling of challenging ingredients such as probiotics.

Opti said the agreement was “an important step” in its business to business (B2B) strategy of utilising its science with partner company expertise and market reach to create multiple products for consumers.

USPL’s pharmaceutical good manufacturing practice (GMP) certification for its probiotic manufacturing facility in New Jersey also offered the possibility of utilising LPLDL in pharmaceutical applications, Opti said.

The agreement gives the firm strategic access to the US probiotic market, the world’s largest with an estimated retail value of US$7.1bn.

Per Rehne, chief commercial director of OptiBiotix, said that the agreement extended the firm’s product offering for LPLDL and had created access to the US market with “an established industry supplier”.

He added that the company would showcase the first formulation from the agreement at the Supply Side West ingredients conference in November.

The agreement follows the second distribution agreement signed for OptiBiotix’s SlimBiome weight management product with South African firm Formulation Creations last week.

In a note to clients, analysts at City broker finnCap said the deal demonstrated the company's ability to "attract high calibre, global partners, eager to utilise the potential inherent within LPLDL".

--Adds broker comment--

]]>
Tue, 09 Oct 2018 07:34:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/206637/optibiotix-inks-agreement-to-manufacture-lpldl-in-us-market-206637.html
<![CDATA[RNS press release - LPLDL® US manufacturing and supply agreement ]]> https://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20181009070003_13820842/ Tue, 09 Oct 2018 07:00:03 +0100 https://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20181009070003_13820842/ <![CDATA[RNS press release - Exercise of Options & Director's Dealing ]]> https://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20181008070005_13819233/ Mon, 08 Oct 2018 07:00:05 +0100 https://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20181008070005_13819233/ <![CDATA[News - OptiBiotix Health unveils second distribution deal of the week for weight management product ]]> https://www.proactiveinvestors.co.uk/companies/news/206258/optibiotix-health-unveils-second-distribution-deal-of-the-week-for-weight-management-product-206258.html OptiBiotix Health plc (LON:OPTI) has unveiled its second distribution agreement of the week for the company’s weight management product SlimBiome.

It has inked a deal with South Africa’s Formulation Creations, led by Gary Coulson, an industry expert with an “extensive network of customers and partners” in his local market.

Formulation already has partnerships with Gold Coast Ingredients, Real Stevia and Cambridge Commodities, OptiBiotix's UK distributor for SlimBiome.

“With such a wealth of local knowledge and technical expertise in the health and wellness sector, we are in a great position to offer the South African market bespoke concepts and weight management products to meet the demands of the local population,” said sales and marketing director Christina Wood.

News flow continues 

This is the AIM-listed group’s fourth piece of material news in ten days.

On Monday OptiBiotix said it had partnered with privately-owned functional foods business CTC Group, which will sell SlimBiome in the Philippines, Vietnam, Indonesia and Colombia.

The tie-up followed hard on the heels of a distribution agreement for its cholesterol product, CholBiome, and news that the group plans to spin out ProBiotix business.

OptiBiotix is a pioneer of the human microbiome, which is essentially the bacteria that inhabit the gut and skin.

It has found, for instance, small changes in the gut flora can affect the way the human body processes food.

Its products are focused on tackling obesity, diabetes and cholesterol.

]]>
Wed, 03 Oct 2018 07:21:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/206258/optibiotix-health-unveils-second-distribution-deal-of-the-week-for-weight-management-product-206258.html
<![CDATA[RNS press release - Non-exclusive distribution agreement for SlimBiome ]]> https://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20181003070002_13813991/ Wed, 03 Oct 2018 07:00:02 +0100 https://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20181003070002_13813991/ <![CDATA[News - OptiBiotix Health agrees functional foods deal with CTC Group ]]> https://www.proactiveinvestors.co.uk/companies/news/206068/optibiotix-health-agrees-functional-foods-deal-with-ctc-group-206068.html Commercial announcements are coming thick and fast from OptiBiotix Health plc (LON:OPTI), which is developing natural remedies for obesity, cholesterol and weight loss.

In its third update in a week, the company said it had agreed on a non-exclusive deal with the privately-owned functional foods business CTC Group, which will distribute weight management product SlimBiome in the Philippines, Vietnam, Indonesia and Colombia.

READ: OptiBiotix Health inks Bulgarian deal for cholesterol product

“This extends our commercialisation of SlimBiome into ASEAN [the Association of South Asian Nations] markets where we have identified a strong consumer need for both weight loss and weight management products,” said OptiBiotix sales and market director, Christina Wood.

The deal follows hard on the heels of a distribution agreement for its cholesterol product, CholBiome, and news that the group plans to spin out ProBiotix business.

OptiBiotix is a pioneer of the human microbiome, which is essentially the bacteria that inhabit the gut and skin.

It has found, for instance, small changes in the gut flora can affect the way the human body processes food.

]]>
Mon, 01 Oct 2018 08:26:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/206068/optibiotix-health-agrees-functional-foods-deal-with-ctc-group-206068.html
<![CDATA[RNS press release - Non-exclusive distribution agreement for SlimBiome ]]> https://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20181001070003_13810039/ Mon, 01 Oct 2018 07:00:03 +0100 https://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20181001070003_13810039/ <![CDATA[Media files - OptiBiotix looking to spin-out divisions to commercialise technologies ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/10617/optibiotix-looking-to-spin-out-divisions-to-commercialise-technologies-10617.html Wed, 26 Sep 2018 11:45:00 +0100 https://www.proactiveinvestors.co.uk/companies/stocktube/10617/optibiotix-looking-to-spin-out-divisions-to-commercialise-technologies-10617.html <![CDATA[News - OptiBiotix Health inks Bulgarian deal for cholesterol product ]]> https://www.proactiveinvestors.co.uk/companies/news/205713/optibiotix-health-inks-bulgarian-deal-for-cholesterol-product-205713.html OptiBiotix Health plc (LON:OPTI) said it has teamed up with an unnamed pharmaceutical and food supplements group to commercialise its CholBiome product in Bulgaria.

With access to 60% of the country’s pharmacies and 15,000 GPs, OptiBiotix’s new partner provides the commercial heft required to get started in this new territory.

WATCH: OptiBiotix looking to spin-out divisions to commercialise technologies

The agreement grants the Bulgarian partner exclusive distribution in return for local product registration. It must hit a three-year sales to target to retain the exclusivity.

First revenues are expected in the first quarter of 2019.

Cholesterol and blood pressure treatment

The product itself is a natural alternative to drugs used to lower cholesterol and blood pressure.

Per Rehné, OptiBiotix’s commercial director, said: "We chose the company for its significant market access in Bulgaria and solid track record for growing product sales.

“This agreement is a strategic step to build the distribution sales channel for CholBiome products in the European market and eliminates intermediates in the supply chain with a shorter route to market and higher value to OptiBiotix.”

Wednesday’s announcement is the second significant update the group has provided to the market this week.

Second big announcement

On Monday, it announced the formation of ProBiotix Health and the appointment of Adam Reynolds as chairman – a precursor to a spin-off of the business.

The new company will be home to cholesterol and blood pressure reducing bacteria strain, LPLDL.

In a statement, investors were told the division has now reached a stage of “scientific and commercial maturity” to make the separation a practical next move.

Reynolds, OptiBiotix chief executive Stephen O’Hara and the team will be hoping to emulate the success of the Skinbiotherapeutics demerger.

An initial £250,000 investment in the business is now worth just shy of £12mln, while the former subsidiary is currently carrying out first in human trials of its potentially breakthrough skin cream.

]]>
Wed, 26 Sep 2018 07:27:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/205713/optibiotix-health-inks-bulgarian-deal-for-cholesterol-product-205713.html
<![CDATA[RNS press release - Distribution agreement for CholBiome® ]]> https://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180926070002_13804476/ Wed, 26 Sep 2018 07:00:02 +0100 https://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180926070002_13804476/ <![CDATA[RNS press release - Director/PDMR Shareholding ]]> https://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180925070023_13802914/ Tue, 25 Sep 2018 07:00:23 +0100 https://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180925070023_13802914/ <![CDATA[News - OptiBiotix planning spin-out of cholesterol and blood pressure technology as it appoints City veteran Reynolds to chair new business ]]> https://www.proactiveinvestors.co.uk/companies/news/205500/optibiotix-planning-spin-out-of-cholesterol-and-blood-pressure-technology-as-it-appoints-city-veteran-reynolds-to-chair-new-business-205500.html OptiBiotix Health plc (LON:OPTI) has appointed City veteran Adam Reynolds to chair its spin-out business, ProBiotix Health, ahead of a separate stock market listing.

The new company will be home to cholesterol and blood pressure reducing bacteria strain, LPLDL.

In a statement, investors were told the division has now reached a stage of “scientific and commercial maturity” to make the separation a practical next move.

Reynolds, OptiBiotix chief executive Stephen O’Hara and the team will be hoping to emulate the success of the Skinbiotherapeutics demerger.

An initial £250,000 investment in the business is now worth just shy of £12mln, while the former subsidiary is currently carrying out first in human trials of its potentially breakthrough skin cream.

Successful strategy 

"The formation of ProBiotix Health and appointment of Adam Reynolds as chairman continues a successful strategy of building value in each division which is materialised by forming separate legal entities and taking them to a public listing,” said boss O’Hara.

“As the listed company grows in value using its own funds, OptiBiotix shareholders benefit from the appreciation of the asset as exemplified by SkinBiotherapeutics.”

OptiBiotix is a pioneer of the human microbiome, which is essentially the bacteria that inhabit the gut and skin.

It has found, for instance, small changes in the gut flora can affect the way the human body processes food.

After spinning off its SkinBio business as a separately-listed entity last year, the group is focused on three development areas – cholesterol, diabetes and weight loss.

finnCap hails change of focus

finnCap, OptiBiotix’s corporate broker, has been impressed with the progress made by CEO O’Hara and his expanded commercial team.

Analyst Mark Brewer in a recent note pointed out the group has transitioned from being technology group to a commercial-focused operation that has negotiated 16 commercial agreements.

These include deals with an offshoot of Premier Foods that makes Birds Custard, Indian giant Tata and Seed Health in the US.

“This significantly de-risks the business,” he added Brewer.

“The focus for the current year will be to begin to convert these agreements into revenues; the timing and quantum of which remain difficult to forecast.” 

The shares were up 4p at 99p, valuing OptiBiotix at £90mln.

]]>
Mon, 24 Sep 2018 07:23:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/205500/optibiotix-planning-spin-out-of-cholesterol-and-blood-pressure-technology-as-it-appoints-city-veteran-reynolds-to-chair-new-business-205500.html
<![CDATA[RNS press release - Formation of ProBiotix Health Limited ]]> https://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180924070013_13801075/ Mon, 24 Sep 2018 07:00:13 +0100 https://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180924070013_13801075/ <![CDATA[Media files - OptiBiotix Health creating multiple channel opportunities across its portfolio ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/10450/optibiotix-health-creating-multiple-channel-opportunities-across-its-portfolio-10450.html Wed, 12 Sep 2018 14:32:00 +0100 https://www.proactiveinvestors.co.uk/companies/stocktube/10450/optibiotix-health-creating-multiple-channel-opportunities-across-its-portfolio-10450.html <![CDATA[News - OptiBiotix secures agreement to market cholesterol-reducing LPLDL in Taiwan ]]> https://www.proactiveinvestors.co.uk/companies/news/204495/optibiotix-secures-agreement-to-market-cholesterol-reducing-lpldl-in-taiwan-204495.html OptiBiotix Health plc (LON:OPTI) has signed a non-exclusive licence agreement with Taiwanese probiotics firm Bened Biomedical Ltd to produce and market products containing its cholesterol and blood pressure-reducing LPLDL strain in the country.

Under the three-year agreement, Bened will produce, package, promote, market, and commercialise products containing the LPLDL strain, with the aim of maximising financial return for both companies.

WATCH: OptiBiotix Health creating multiple channel opportunities across its portfolio

The agreement follows a memorandum signed between AIM-listed OptiBiotix and Bendel last September, which provided a 12-month period to explore licensing and sales opportunities for the LPLDL strain.

A similar licensing agreement for Opti’s cholesterol-lowering bacteria was also signed with an unnamed US firm last week, who plans to use the bacteria to create a high-value pharmaceutical drug, potentially generating several six and seven-figure payments for the group.

The company said the agreement would expand its sales in Taiwan, where the supplements market is expected to grow 27% by 2021, as well as having the potential to broaden its opportunities in the Asia-Pacific region.

Per Rehne, commercial director of OptiBiotix, added that the agreement, its 13th for the LPLDL strain in the last 18 months, enhanced the firm’s presence in Asia-Pacific while also allowing the firm to “offer multiple product solutions” through partnerships with consumer health and pharma companies.

In a separate announcement, OptiBiotix also announced the appointment of Sean Christie, the former finance director of FTSE 100 chemical company Croda PLC (LON:CRDA), as a non-executive director.

In mid-morning trading Monday, OptiBiotix shares were up 1.4% at 103.5p.

--Adds share price--

]]>
Mon, 10 Sep 2018 07:37:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/204495/optibiotix-secures-agreement-to-market-cholesterol-reducing-lpldl-in-taiwan-204495.html
<![CDATA[RNS press release - Director Appointment ]]> https://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180910070007_13783853/ Mon, 10 Sep 2018 07:00:07 +0100 https://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180910070007_13783853/ <![CDATA[RNS press release - Exercise of Warrants and Issue of Equity ]]> https://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180910070004_13783780/ Mon, 10 Sep 2018 07:00:04 +0100 https://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180910070004_13783780/ <![CDATA[Media files - US deal launches OptiBiotix's LPLDL probiotic into huge pharma space ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/10349/us-deal-launches-optibiotix-s-lpldl-probiotic-into-huge-pharma-space-10349.html Wed, 05 Sep 2018 15:00:00 +0100 https://www.proactiveinvestors.co.uk/companies/stocktube/10349/us-deal-launches-optibiotix-s-lpldl-probiotic-into-huge-pharma-space-10349.html <![CDATA[News - OptiBiotix Health agrees US licensing deal for cholesterol-lowering bacteria ]]> https://www.proactiveinvestors.co.uk/companies/news/204092/optibiotix-health-agrees-us-licensing-deal-for-cholesterol-lowering-bacteria-204092.html OptiBiotix Health PLC (LON:OPTI) has licensed out its cholesterol-lowering bacteria to an unnamed US company, which plans to use it to create a high-value pharmaceutical drug.

Financial details of the deal weren’t disclosed; however, OptiBiotix said it would receive a six-figure payment on the official signing of the agreement and two ‘milestone’ awards totalling seven figures.

WATCH: OptiBiotix focused on accelerating revenue after 'exciting period of growth'

An additional six-figure amount, plus royalties on future sales, would be due if a product was launched.

OptiBiotix would receive a seven-figure payment should the American business decide to exercise its option to broaden the licence agreement out to a global deal.

Development assured

Under the terms currently agreed, the US company would take responsibility for the development of the Lactobacillus plantarum bacteria strain as a pharmaceutical product in the States, the world’s largest drugs market.

This would include pre-clinical and human clinical testing, regulatory filings and approvals, product manufacture, marketing and product sales.

OptiBiotix would manufacture the base ingredient.

“This is a substantive investment by our US partner which recognises the potential of our strain and the scale of the opportunity in one of the largest and fastest growing markets around the world," said chief executive Stephen O’Hara.

The shares, up 72% in the year to date, advanced a further 5% in morning trade to 104p. This values the business at £87mln.

-- Adds share price --

 

]]>
Tue, 04 Sep 2018 07:27:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/204092/optibiotix-health-agrees-us-licensing-deal-for-cholesterol-lowering-bacteria-204092.html
<![CDATA[RNS press release - OptiBiotix signs US pharmaceutical deal ]]> https://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180904070004_13777402/ Tue, 04 Sep 2018 07:00:04 +0100 https://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180904070004_13777402/ <![CDATA[Media files - OptiBiotix focused on accelerating revenue after 'exciting period of growth' ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/10282/optibiotix-focused-on-accelerating-revenue-after-exciting-period-of-growth--10282.html Thu, 30 Aug 2018 13:20:00 +0100 https://www.proactiveinvestors.co.uk/companies/stocktube/10282/optibiotix-focused-on-accelerating-revenue-after-exciting-period-of-growth--10282.html <![CDATA[News - OptiBiotix signs seven new manufacturing and supply agreements in “exciting” first half ]]> https://www.proactiveinvestors.co.uk/companies/news/203851/optibiotix-signs-seven-new-manufacturing-and-supply-agreements-in-exciting-first-half-203851.html The chief executive of OptiBiotix Health PLC (LON:OPTI) has hailed the past six months as an “exciting period of growth” for the life sciences group.

AIM-quoted Opti has been striking manufacturing and distribution deals around the world as it looks to commercialise its cholesterol and blood pressure-reducing LPLDL strain, SlimBiome hunger-free weight management system and low-calorie sugar alternative SweetBiotix.

READ: First supplement containing LPLDL launched in US

During the six months ended May 30, the company signed seven new agreements which will see its compounds made and sold in the UK, Europe, USA and Asia. In total, Opti has signed 19 deals since March 2017.

OptiBiotix has also made strides with its management, bringing on board food industry veteran and former Express Dairies and Arla Foods chief executive Neil Davidson as its new non-executive chairman at the end of 2017.

“The last six months has been an exciting period of growth and development for us,” said chief executive Stephen O’Hara.

“As the nineteen deals we have signed since March 2017 translate into an increasing range of products and territories across the world there is an opportunity to deliver significant revenue growth.

“We have been particularly pleased with the increased interest from pharmaceutical companies in developing LPLDL® as a drug product called a biotherapeutic, which creates the possibility of high, value deals in a number of territories in the future.”

He added: “Our online store is now ready for launch and we plan to go live with it in September 2018. This will create another channel to market our products, with the potential to become a division in its own right.”

READ: Opti investors like what they see

Revenue inched up to £80,600 in the first half, up from £74,900 a year earlier, although Opti swung to a pre-tax loss of £1.19mln (H1 17: profit of £3.12mln). Last year’s figures were skewed by a revaluation of its investment in SkinBioTherapeutics PLC (LON:SKIN).

Costs were broadly the same at £1.02mln (H1 17: £1.02mln). At the end of the period, Opti had cash reserves of £1.80mln which is “sufficient to cover the delivery of existing development and commercial plans”.

]]>
Thu, 30 Aug 2018 07:48:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/203851/optibiotix-signs-seven-new-manufacturing-and-supply-agreements-in-exciting-first-half-203851.html
<![CDATA[RNS press release - Half-year Report ]]> https://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180830070004_13772189/ Thu, 30 Aug 2018 07:00:04 +0100 https://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180830070004_13772189/ <![CDATA[Media files - OptiBiotix Health sees revenues build as agreements turn into commercial deals ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/10200/optibiotix-health-sees-revenues-build-as-agreements-turn-into-commercial-deals-10200.html Wed, 22 Aug 2018 08:25:00 +0100 https://www.proactiveinvestors.co.uk/companies/stocktube/10200/optibiotix-health-sees-revenues-build-as-agreements-turn-into-commercial-deals-10200.html <![CDATA[RNS press release - Proposed directorate change ]]> https://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180806070007_13744122/ Mon, 06 Aug 2018 07:00:07 +0100 https://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180806070007_13744122/ <![CDATA[RNS press release - Director's dealing ]]> https://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180731100434_13737622/ Tue, 31 Jul 2018 10:04:34 +0100 https://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180731100434_13737622/ <![CDATA[Media files - Optibiotix is a very clever business model says chairman ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/9906/optibiotix-is-a-very-clever-business-model-says-chairman-9906.html Thu, 19 Jul 2018 15:16:00 +0100 https://www.proactiveinvestors.co.uk/companies/stocktube/9906/optibiotix-is-a-very-clever-business-model-says-chairman-9906.html <![CDATA[Media files - Investors 'beginning to realise the potential' in OptiBiotix Health - CEO ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/9873/investors-beginning-to-realise-the-potential-in-optibiotix-health-ceo-9873.html Tue, 17 Jul 2018 13:12:00 +0100 https://www.proactiveinvestors.co.uk/companies/stocktube/9873/investors-beginning-to-realise-the-potential-in-optibiotix-health-ceo-9873.html <![CDATA[RNS press release - Grant of Options ]]> https://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180717070011_13719899/ Tue, 17 Jul 2018 07:00:11 +0100 https://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180717070011_13719899/ <![CDATA[RNS press release - Director's dealing ]]> https://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180712070007_13714763/ Thu, 12 Jul 2018 07:00:07 +0100 https://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180712070007_13714763/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180706120003_13708975/ Fri, 06 Jul 2018 12:00:03 +0100 https://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180706120003_13708975/ <![CDATA[RNS press release - Result of AGM ]]> https://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180704140754_13705788/ Wed, 04 Jul 2018 14:07:54 +0100 https://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180704140754_13705788/ <![CDATA[News - OptiBiotix appoints director of research & development ]]> https://www.proactiveinvestors.co.uk/companies/news/200102/optibiotix-appoints-director-of-research-development-200102.html OptiBiotix Health PLC (LON:OPTI) said it has appointed Dr Sofia Kolyda as director of research & development with immediate effect.

The AIM-listed life sciences group, which develops compounds to tackle obesity, high cholesterol, and diabetes, said Kolyda’s expertise had been important in the development of its technology through laboratory studies, human studies and manufacturing scale up, which had allowed it to create a pipeline of products.

WATCH: OptiBiotix Health sees revenues build as agreements turn into commercial deals

The firm added that Kolyda’s scientific leadership had been key to the company winning best scientific publication at the Probiota industry event in 2017 and 2018.

OptiBiotix also said that under Kolyda’s tenure it had secured agreements with several global corporates, including Tata for microbiome modulation and two agreements for its SweetBiotix range of sweeteners, the first with one of the world's largest suppliers of nutritional products and the second with one of the world's largest providers of dairy products.

Given the high levels of interest in SweetBiotix, Kolyda would take responsibility for leading development programmes with current and future corporate partners.

]]>
Wed, 04 Jul 2018 08:05:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/200102/optibiotix-appoints-director-of-research-development-200102.html
<![CDATA[RNS press release - Directorate Change ]]> https://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180704070004_13704571/ Wed, 04 Jul 2018 07:00:04 +0100 https://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180704070004_13704571/ <![CDATA[News - OptiBiotix signs agreement with global corporate for SweetBiotix product ]]> https://www.proactiveinvestors.co.uk/companies/news/199549/optibiotix-signs-agreement-with-global-corporate-for-sweetbiotix-product-199549.html OptiBiotix Health PLC (LON:OPTI) has announced that it has entered into an agreement with a global corporate for its SweetBiotix low-calorie sweet fibres.

The FTSE 100-listed firm said the agreement sets out the terms and grants exclusivity, for a period of six months, to negotiate a license agreement for the scale-up, manufacture and distribution of its SweetBiotix product.

READ: OptiBiotix inks licence agreement for LPLDL compound in Italy

The life sciences company said it will receive monthly payments during this exclusivity period amounting to a six-figure sum

OptiBiotix did not reveal the name of the company, but said it is a global supplier of nutritional and agricultural products to companies around the world with an annual turnover exceeding US$100bn.

Stephen O'Hara, CEO of OptiBiotix, commented: “This is the second agreement with global partners for products created from our SweetBiotix development programmes. This is part of a strategy of working with global partners to support scale-up, manufacture and commercialisation of a range of SweetBiotix products in well-known consumer brands.”

He added: “With international concerns over the balance of sugars and fibres in consumer diets rising, OptiBiotix's is at the forefront of product development in this area of growing industry and commercial interest."

In a note to clients, analysts at finnCap said: “Whilst there is no certainty that the negotiations will lead to a full licence, this agreement could be very substantial given the scale of the corporate with which it has had initial discussions.”

In morning trading, OptiBiotix shares jumped 3.8% to 67.00p.

 -- Adds broker comment, share price --

]]>
Tue, 26 Jun 2018 07:28:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/199549/optibiotix-signs-agreement-with-global-corporate-for-sweetbiotix-product-199549.html
<![CDATA[RNS press release - Agreement with global corporate for SweetBiotix® ]]> https://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180626070001_13692994/ Tue, 26 Jun 2018 07:00:01 +0100 https://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180626070001_13692994/ <![CDATA[Media files - OptiBiotix Health Plc enters into exclusive licensing deal for LPLDL in Italy ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/9640/optibiotix-health-plc-enters-into-exclusive-licensing-deal-for-lpldl-in-italy-9640.html Thu, 21 Jun 2018 08:01:00 +0100 https://www.proactiveinvestors.co.uk/companies/stocktube/9640/optibiotix-health-plc-enters-into-exclusive-licensing-deal-for-lpldl-in-italy-9640.html <![CDATA[News - OptiBiotix inks licence agreement for LPLDL compound in Italy ]]> https://www.proactiveinvestors.co.uk/companies/news/199285/optibiotix-inks-licence-agreement-for-lpldl-compound-in-italy-199285.html OptiBiotix Health plc (LON:OPTI) has signed a licence agreement to commercialise food supplements containing its LPLDL strain in the Italian market.

The AIM-listed life sciences company, which develops compounds to tackle obesity, high cholesterol, diabetes and skin care, said the 10-year agreement would grant ALFASIGMA, a multinational pharmaceutical company, a licence to promote food supplements containing the LPLDL strain for cardiovascular health, throughout Italy. 

READ: First supplement containing OptiBiotix’s breakthrough cholesterol-lowering strain launched in U

The group added that the agreement would include an upfront payment and royalties with five-figure guaranteed minimum payments.

Italy is the largest probiotic supplement market in Europe and the second largest market in the world with a value of over US$500mln and a 25% per annum growth forecast to 2021.

Per Rehne, commercial director of OptiBiotix, said: “This agreement is another deal from a very strong pipeline with industry partners of increasing size and revenue potential targeted at the largest and fastest growing markets around the world."

The agreement follows the launch of OptiBiotix’s LPLDL strain in the US market after the company struck a deal with US supplement maker, Seed Health, in May.

]]>
Thu, 21 Jun 2018 07:35:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/199285/optibiotix-inks-licence-agreement-for-lpldl-compound-in-italy-199285.html
<![CDATA[RNS press release - Exclusive license agreement for LPLDL® ]]> https://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180621070003_13687809/ Thu, 21 Jun 2018 07:00:03 +0100 https://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180621070003_13687809/ <![CDATA[News - OptiBiotix strikes SlimBiome manufacturing and supply deal with Morley Foods ]]> https://www.proactiveinvestors.co.uk/companies/news/198997/optibiotix-strikes-slimbiome-manufacturing-and-supply-deal-with-morley-foods-198997.html OptiBiotix Health plc (LON:OPTI) has signed an exclusive deal with John Morley Foods to manufacture and supply SlimBiome in muesli packs within the UK.

Morleys supplies ingredients to major retailers and several consumer food brands and has spent the last six months developing a range of muesli products which contain SlimBiome – a patented combination of natural ingredients which provide hunger-free weight loss.

READ: First supplement containing OptiBiotix’s breakthrough cholesterol-lowering strain launched in US

The muesli will be sold as own-label products to major retailers and as extensions to existing well-known brands.

Alongside the manufacturing and supply part of the deal, Morleys’ job is also to promote the SlimBiome muesli packs. In return for its efforts, Morleys will take 50% cut of any profits generated.

“We chose Morleys due to their reputation as one of the UK's leading suppliers of specialist ingredients and the energy and passion they have shown in developing a wide range of muesli products containing SlimBiome over the last six months,” said chief executive Stephen O’Hara.

“We believe working with Morleys, and similar partners around the world, provides the best opportunity of meeting the requirements of major retailers and global brands who are looking to develop healthy products to meet growing consumer demand.”

]]>
Mon, 18 Jun 2018 07:36:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/198997/optibiotix-strikes-slimbiome-manufacturing-and-supply-deal-with-morley-foods-198997.html
<![CDATA[RNS press release - Manufacturing agreement with Morley Foods ]]> https://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180618070004_13682605/ Mon, 18 Jun 2018 07:00:04 +0100 https://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180618070004_13682605/ <![CDATA[RNS press release - Exercise of Options and Issue of Equity ]]> https://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180614070003_13679006/ Thu, 14 Jun 2018 07:00:03 +0100 https://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180614070003_13679006/ <![CDATA[RNS press release - Notice of AGM ]]> https://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180611070004_13673674/ Mon, 11 Jun 2018 07:00:04 +0100 https://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180611070004_13673674/ <![CDATA[News - First supplement containing OptiBiotix’s breakthrough cholesterol-lowering strain launched in US ]]> https://www.proactiveinvestors.co.uk/companies/news/198419/first-supplement-containing-optibiotixs-breakthrough-cholesterol-lowering-strain-launched-in-us-198419.html A dietary supplement containing OptiBiotix Health plc’s (LON:OPTI) cholesterol and blood pressure-reducing LPLDL strain has launched in the US.

Seed Health struck a deal with AIM-quoted Opti to produce, market and commercialise products containing the LPLDL strain in May.

READ: OptiBiotix inks US deal for breakthrough cholesterol strain

The US supplements maker has now launched its Daily Symbiotic capsules which can be bought directly through its website.

It is a significant achievement for OptiBiotix, marking its entry into one of the largest and fastest-growing probiotic markets in the world and one which is expected to be worth more than US$3bn by 2021.

Boss wants more product launches

“We are excited to see the launch of products containing our cholesterol reducing LPLDL strain in the USA, the world's largest and fastest growing probiotic market,” said Opti’s chief executive Stephen O’Hara.

“The launch with Seed substantiates the science behind LPLDL and helps build the LPLDL brand in the consumer healthcare market around the world.”

He added: “We hope this will be the first of many product launches of multiple formulations and presentations of LPLDL as the active component in a wide range of products in the USA and around the world.”

]]>
Thu, 07 Jun 2018 07:31:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/198419/first-supplement-containing-optibiotixs-breakthrough-cholesterol-lowering-strain-launched-in-us-198419.html
<![CDATA[RNS press release - US launch of LPLDL® with Seed Health ]]> https://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180607070004_13670040/ Thu, 07 Jun 2018 07:00:04 +0100 https://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180607070004_13670040/ <![CDATA[News - OptiBiotix signs evaluation agreement with a global dairy company for SweetBiotix product ]]> https://www.proactiveinvestors.co.uk/companies/news/197982/optibiotix-signs-evaluation-agreement-with-a-global-dairy-company-for-sweetbiotix-product-197982.html OptiBiotix Health plc (LON:OPTI) has announced it has entered into an evaluation agreement with a global dairy company for its SweetBiotix calorie-free sweet fibres.

The AIM-listed company said the agreement grants a non-exclusive licence for an evaluation period to explore the potential for using the SweetBiotix technology to reduce the sugar content in a range of its dairy food products.

READ: OptiBiotix Health raises £1.5mln in oversubscribed placing to capitalise on opportunities

OptiBiotix revealed that the undisclosed company is a global brand and one of the world’s largest providers of dairy products with an annual turnover exceeding US$10bn.

The company, which is developing compounds to tackle obesity, high cholesterol and diabetes, has previously announced that the five successful human taste studies on the SweetBiotix product development had created interest from several companies.

OPtiBiotix said this agreement reflects interest from one of these companies in exploring the use of SweetBiotix in its branded dairy products.

Stephen O’Hara, CEO of the company, said: “This is part of a strategy of working with global partners who have the capability and expertise to manufacture speciality ingredients like SweetBiotix and well-known consumer brands who have the specialist application expertise to incorporate this technology in to their own branded breaded, dairy, cereal and beverage consumer products.”

He added: “This approach provides a low-risk way to fully exploit the wide range of opportunities offered by our SweetBiotix technology.”

]]>
Thu, 31 May 2018 07:32:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/197982/optibiotix-signs-evaluation-agreement-with-a-global-dairy-company-for-sweetbiotix-product-197982.html